Acadian Asset Management LLC lifted its position in Haemonetics Corporation (NYSE:HAE) by 100.8% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 524,768 shares of the medical instruments supplier’s stock after purchasing an additional 263,432 shares during the period. Acadian Asset Management LLC’s holdings in Haemonetics were worth $30,479,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. Tudor Investment Corp ET AL lifted its holdings in shares of Haemonetics by 0.5% in the second quarter. Tudor Investment Corp ET AL now owns 28,126 shares of the medical instruments supplier’s stock worth $1,111,000 after buying an additional 143 shares in the last quarter. Amalgamated Bank lifted its holdings in shares of Haemonetics by 5.7% in the second quarter. Amalgamated Bank now owns 7,322 shares of the medical instruments supplier’s stock worth $289,000 after buying an additional 392 shares in the last quarter. The Manufacturers Life Insurance Company lifted its holdings in shares of Haemonetics by 1.2% in the second quarter. The Manufacturers Life Insurance Company now owns 39,906 shares of the medical instruments supplier’s stock worth $1,575,000 after buying an additional 488 shares in the last quarter. UBS Asset Management Americas Inc. lifted its holdings in shares of Haemonetics by 2.7% in the second quarter. UBS Asset Management Americas Inc. now owns 28,153 shares of the medical instruments supplier’s stock worth $1,112,000 after buying an additional 742 shares in the last quarter. Finally, Rothschild Asset Management Inc. lifted its holdings in shares of Haemonetics by 1.5% in the third quarter. Rothschild Asset Management Inc. now owns 89,178 shares of the medical instruments supplier’s stock worth $4,001,000 after buying an additional 1,320 shares in the last quarter.

In related news, Director Susan Bartlett Foote sold 16,926 shares of the firm’s stock in a transaction that occurred on Friday, November 10th. The shares were sold at an average price of $54.19, for a total value of $917,219.94. Following the sale, the director now directly owns 27,313 shares of the company’s stock, valued at $1,480,091.47. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ronald G. Gelbman sold 5,440 shares of the stock in a transaction that occurred on Thursday, November 16th. The shares were sold at an average price of $56.69, for a total transaction of $308,393.60. The disclosure for this sale can be found here. Insiders sold 54,486 shares of company stock worth $3,050,827 over the last ninety days. 1.20% of the stock is currently owned by insiders.

Shares of Haemonetics Corporation (HAE) opened at $64.39 on Friday. The firm has a market cap of $3,437.94, a P/E ratio of 804.98, a P/E/G ratio of 4.91 and a beta of 0.99. The company has a debt-to-equity ratio of 0.22, a current ratio of 2.17 and a quick ratio of 1.51. Haemonetics Corporation has a one year low of $36.44 and a one year high of $65.25.

Haemonetics (NYSE:HAE) last announced its earnings results on Tuesday, November 7th. The medical instruments supplier reported $0.48 earnings per share for the quarter, beating analysts’ consensus estimates of $0.41 by $0.07. The business had revenue of $225.40 million for the quarter, compared to the consensus estimate of $219.12 million. Haemonetics had a net margin of 0.50% and a return on equity of 11.16%. Haemonetics’s quarterly revenue was up 2.3% on a year-over-year basis. During the same period last year, the firm posted $0.38 earnings per share. equities analysts anticipate that Haemonetics Corporation will post 1.69 EPS for the current fiscal year.

A number of brokerages have recently issued reports on HAE. Zacks Investment Research downgraded shares of Haemonetics from a “buy” rating to a “hold” rating in a report on Wednesday, January 10th. Jefferies Group increased their price target on shares of Haemonetics from $18.00 to $75.00 and gave the stock a “buy” rating in a report on Monday, January 8th. Raymond James Financial raised shares of Haemonetics from an “underperform” rating to a “market perform” rating in a report on Tuesday, January 2nd. Morgan Stanley raised shares of Haemonetics from an “equal weight” rating to an “overweight” rating and set a $51.00 price target on the stock in a report on Tuesday, January 2nd. Finally, Craig Hallum reissued a “hold” rating and issued a $50.00 price target (up from $40.00) on shares of Haemonetics in a report on Wednesday, November 8th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company’s stock. Haemonetics has a consensus rating of “Hold” and an average price target of $58.83.

TRADEMARK VIOLATION NOTICE: “Acadian Asset Management LLC Raises Holdings in Haemonetics Corporation (HAE)” was reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.watchlistnews.com/acadian-asset-management-llc-raises-holdings-in-haemonetics-corporation-hae/1814876.html.

Haemonetics Profile

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Corporation (NYSE:HAE).

Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.